56844-38-3

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
2,4-Dichloro-5-methyl-thieno[2,3-d]pyrimidine serves as an intermediate in the synthesis of various pharmaceutical and agrochemical products. Its unique structure and functional groups make it a valuable component in the development of new drugs and agrochemicals with specific therapeutic or pesticidal properties.
Used as a Building Block in Organic Chemistry:
2,4-Dichloro-5-methyl-thieno[2,3-d]pyrimidine is also utilized as a building block in the preparation of diverse organic compounds. Its structural features allow for further chemical modifications and reactions, facilitating the creation of new molecules with potential applications in various fields.
Used in Medicinal Chemistry and Drug Discovery:
2,4-Dichloro-5-methyl-thieno[2,3-d]pyrimidine has potential applications in the field of medicinal chemistry and drug discovery. Its ability to be modified and incorporated into complex molecular structures positions it as a promising candidate for the development of novel therapeutic agents and active pharmaceutical ingredients.

InChI:InChI=1/C7H4Cl2N2S/c1-3-2-12-6-4(3)5(8)10-7(9)11-6/h2H,1H3

Upstream product

• 75860-79-6 5-methylthieno<2,3-d>pyrimidine-2,4-dione 
• 4623-55-6 2-amino-4-methylthiophene-3-carbonitrile 
• 503-38-8 trichloromethyl chloroformate 

Downstream Products

• 181374-33-4 2-chloro-5-methyl-4-benzylamino-thieno-[2,3-d]-pyrimidine 
• 83259-31-8 2-chloro-5-methylthieno[2,3-d]pyrimidine 
• 1030377-48-0 C₂₂H₂₄N₈OS 
• 1030377-70-8 5-methyl-2-{(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl}thieno[2,3-d]pyrimidine 

Relevant academic research and scientific papers

Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis

Recent clinical studies have demonstrated that dual orexin receptor antagonists (OX1R and OX2R antagonists or DORAs) represent a novel treatment option for insomnia patients. Previously we have disclosed several compounds in the diazepane amide DORA series with excellent potency and both preclinical and clinical sleep efficacy. Additional SAR studies in this series were enabled by the expansion of the acetonitrile-assisted, diphosgene-mediated 2,4-dichloropyrimidine synthesis to novel substrates providing an array of Western heterocycles. These heterocycles were utilized to synthesize analogs in short order with high levels of potency on orexin 1 and orexin 2 receptors as well as in vivo sleep efficacy in the rat.

The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes

New dipeptidyl peptidase IV inhibitors were designed based on Alogliptin using a scaffold-hopping strategy. All of the compounds constructed on a thienopyrimidine scaffold demonstrated good inhibition and selectivity for DPP-IV. Compound 10d exhibited subnanomolar (IC50 = 0.33 nM) DPP-IV inhibitory activity, good in vivo efficacy and an acceptable pharmacokinetic profile. A pharmacokinetic-driven optimization of 10d may lead to a new class of clinical candidate DPP-IV inhibitors.

Substituted diazepan orexin receptor antagonists

The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.